Joshua Silverwood

United Kingdom

News Reporter at Medical Device Network

News Reporter at Clinical Trials Arena

Senior reporter for the Vet Times.

Featured in: Favicon

mirror.co.uk Favicon

dailyrecord.co.uk Favicon

inyourarea.co.uk Favicon

countypress.co.uk Favicon

vettimes.co.uk Favicon

msn.com

yahoo.com (+1) Favicon

pharmaceutical-technology.com Favicon

clinicaltrialsarena.com Favicon

medicaldevice-network.com + 3 more

Articles

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

2 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease whilst also surpassing the blood-brain barrier. The Phase I single ascending dose (SAD) and multiple ascending dose (MAD) trial (EUCT-2023-507910-28-00) found ARV-102, a proteolysis targeting chimaera (PROTAC) therapy, led to a drop in leucine-rich repeat kinase 2 (LRRK2) across healthy volunteers.
Lundbeck’s superagonist prompts 61.2% seizure reduction

2 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies (DEEs) has seen a 61.2% reduction in total seizures in a Phase Ib/IIa trial.
BeiGene halts ociperlimab amid poor Phase III trial predictions

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab, after an independent committee ruled that it was unlikely to meet its primary endpoint of impacting overall survival (OS) in a Phase III trial.
Roche’s high-dose Ocrevus fails primary endpoint in MS trial

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in patients living with relapsing multiple sclerosis (MS) has not met its primary endpoint.
Desentum to advance pollen allergy vaccine after positive Phase I trial

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

A vaccine designed to ward against allergic reactions brought on by birch pollen has proven to be safe and well-tolerated while showing early and sustained signs of efficacy. Finnish biopharma Desentum Oy is advancing the vaccine, dubbed DM-101PX, to Phase II studies after it announced positive results from a randomised, double-blind, placebo-controlled Phase I trial (NCT04266028). The trial investigated the short-course treatment in patients allergic to birch pollen.
Compass’s tovecimig meets primary endpoint in Phase II/III BTC trial

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

Compass Therapeutics has announced top-line data from its COMPANION-002 trial investigating tovecimig, an antibody-based therapeutic for biliary tract cancer (BTC). Results from the Phase II/III trial found that one patient dosed with a combination of tovecimig alongside chemotherapy drug paclitaxel achieved a complete response and 17.1% of patients achieved an overall response rate (ORR), compared to 5.3% ORR for patients treated with paclitaxel alone.
Tenaya highlights HCM gene therapy interim data at ACC 2025

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

Three patients living with objectively severe heart disease have had their limitations on physical activity lifted following a single dose of Tenaya Therapeutics’ gene therapy TN-201, according to interim data from the company’s Phase Ib/2 trial.
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

AstraZeneca’s AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of participants reach the recommended LDL-C target, compared to just 13% with statins alone.
Cleerly CONFIRM2 study finds women with CAD at higher risk of MACE

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

Cleerly has announced interim results from a trial, described as the largest-ever cardiovascular phenotype outcomes study, finding that women living with chronic coronary artery disease (CAD) are at higher risk of major adverse coronary events (MACE) than men. The Cleerly CONFIRM2 trial was a retrospective and prospective, open-label trial that examined 3,551 patients to determine if AI-based Quantitative Computed Tomography (AI-QCT) could be used to predict mortality and MACE.
Transcend’s PTSD therapy shows potential in Phase II trial

3 weeks ago | clinicaltrialsarena.com | Joshua Silverwood

Transcend Therapeutics’ Phase II IMPACT-1 study examining its neuroplastigen treatment for post-traumatic stress disorder (PTSD), dubbed TSND-201, has met its primary endpoint eliciting a statistically significant drop in symptoms versus placebo. The study included 65 patients diagnosed with severe PTSD (CAPS-5 score ≥ 35), all of whom had previously undergone PTSD treatment. They were administered four oral doses of either TSND-201 or a placebo, with each dose spaced one week apart.